Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 12:10:19 GMT 2023
by
admin
on
Sat Dec 16 12:10:19 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
RES3V2K0VC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
RES3V2K0VC
Created by
admin on Sat Dec 16 12:10:19 GMT 2023 , Edited by admin on Sat Dec 16 12:10:19 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_113 | 1_190 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_4 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
AGONIST
Ki
|
||
|
INHIBITOR -> TARGET |
Tepotinib also inhibited melatonin 2 and
imidazoline 1 receptors at clinically achievable concentrations.
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
AGONIST
Ki
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|